Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.17 USD
+0.02 (0.94%)
Updated Oct 2, 2024 03:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Innate Pharma S.A. Sponsored ADR (IPHA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.63 | $11.50 | $5.00 | 301.40% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Innate Pharma S.A. Sponsored ADR comes to $8.63. The forecasts range from a low of $5.00 to a high of $11.50. The average price target represents an increase of 301.4% from the last closing price of $2.15.
Analyst Price Targets (4 )
Broker Rating
Innate Pharma S.A. Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/16/2024 | Evercore Partners | Liisa A Bayko | Not Available | Strong Buy |
9/13/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/15/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $8.63 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | NA |
IPHA FAQs
Innate Pharma S.A. Sponsored ADR (IPHA) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Innate Pharma S.A. Sponsored ADR (IPHA) is $8.63. The current on short-term price targets is based on 2 reports.
The forecasts for Innate Pharma S.A. Sponsored ADR (IPHA) range from a low of $5 to a high of $11.5. The average price target represents a increase of $301.40 from the last closing price of $2.15.
The current UPSIDE for Innate Pharma S.A. Sponsored ADR (IPHA) is 301.40%
Based on short-term price targets offered by four analysts, the average price target for Innate Pharma S.A. Sponsored ADR comes to $8.63. The forecasts range from a low of $5.00 to a high of $11.50. The average price target represents an increase of 301.4% from the last closing price of $2.15.